Perceptive Advisors LLC

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Perceptive Advisors LLC
CRD #154703
SEC #801-71841
CIK #0001224962
AUM 11.77 B (2026-03-30)
Employees 49 (57% Investors, 0% Brokers)
Fees
Minimum
Phone646-205-5300
Address51 Astor Place
New York, NY 10003
Source [IAPD] [EDGAR] [Website] [LinkedIn]
Total AUM ($B)
151296302008201420202027
In the News
Thu, 30 Jul 2026 Perceptive Advisors LLC Initiates a Major Stake in Perceptive Ca — GuruFocus
Fri, 10 Jul 2026 LeonaBio (LONA) awards 28,000 stock options tied to Perceptive Advisors board role — Stock Titan
Tue, 07 Apr 2026 Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors — Yahoo Finance
Fees and Compensation — Form ADV Part 2A (7/13/2026) [Brochure]
ITEM 5: FEES AND COMPENSATION

The Advisor receives compensation for its advisory services, including management fees and performance-
based compensation, as set forth in the applicable governing documents of the funds and other investment
vehicles it advises. Fee structures vary depending on the applicable fund, vehicle, investor class and
strategy.

The Perceptive Life Sciences Funds

The Advisor receives a management fee (the “Management Fee”), payable at the feeder fund level,
calculated based on the net asset value of the Perceptive Life Sciences Funds. The Management Fee is
payable monthly at the beginning of each month. Management Fee calculation methodology is described
in detail in each feeder fund’s Governing Documents.

The Advisor, in its discretion, may waive all or any portion of the Management Fee for any investor and
may agree that a portion of its Management Fee be paid to third parties.

Each feeder fund also reimburses and/or advances to the Advisor a maximum of 1% per annum of the
average month-end net asset value of each feeder fund for certain of the Advisor’s administrative and
management costs and expenses, including without limitation computer equipment and services, office
space and utilities, salaries and bonuses, and other overhead expenses of the Advisor, except to the extent
such costs and expenses are provided through “soft dollars” as described in Item 12 herein. Certain
investors in the feeder funds hold shares or limited partnership interests that are not subject to this 1% fee.

Please see Item 6 for a discussion of the Advisor’s performance-based compensation.

The Credit Opportunities Funds

The Advisor receives a Management Fee, calculated and payable quarterly in advance. Management Fee
calculation methodology is described in detail in each Credit Opportunities Fund’s Governing Documents.

Please see Item 6 for a discussion of the Advisor’s performance-based compensation.

The Venture Funds

The Advisor receives a Management Fee, calculated and payable quarterly in advance. Management Fee
calculation methodology is described in detail in each Venture Fund’s Governing Documents.

Please see Item 6 for a discussion of the Advisor’s performance-based compensation.

The Capital Solutions Funds

The Advisor receives a Management Fee, calculated and payable quarterly in advance. Management Fee
calculation methodology is described in detail in the Capital Solutions Fund’s Governing Documents.

The Adviser, in its discretion, may waive a portion of the Management Fee in exchange for a reduction in
the Adviser’s cash capital contribution obligation and/or corresponding interest in the Capital Solutions
Funds’ profits.

Please see Item 6 for a discussion of the Advisor’s performance-based compensation.

The Advisor, in its discretion, may waive all or any portion of the Management Fee for any investor.
Generally 100% of the Life Sciences Funds’ the Credit Opportunity Funds’, the Venture Funds’ and Capital
Solutions Fund’s pro rata share of any amount of director’s fees, consulting fees, commitment fees, break-
up fees, monitoring fees, success fees or other remuneration paid to the general partner of the applicable
fund, the Advisor or any of the Advisor’s principals by or on behalf of portfolio companies, net of expenses,
will be treated as an offset against future Management Fees or will reduce Fund expenses; provided,
however, that the Management Fee will not be reduced below zero for the applicable fund. Generally, either
the Advisor bears the costs of any placement fees for its Funds, or any such fees offset the Management
Fee of the applicable fund.

Separate Account

The Separate Account is not charged any fees by the Advisor.

Co-investment Vehicles

The Advisor establishes specific fee schedules with respect to each co-investment vehicle. Fees on co-
investment vehicles may be greater than, equal to, or lower than, the fees applicable to the Client Accounts
alongside which co-investment vehicles participate in investment opportunities, and may include reduced
or no management fees, different carried interest or incentive allocations, and/or different expense
arrangements. The Advisor, in its sole discretion, may waive or lower the fees for some or all of the
investors in the co-investment vehicle. Such waiver or reduction of the fees will not result in any increase
in the fee or expense burden on other investors in the co-investment vehicles.

Expenses

Except as otherwise agreed with any particular Client Account in the relevant Governing Documents,
generally each Client Account is responsible for, among other things, all third-party costs and expenses
related to their investments and operations, including all expenses and costs incurred in investigating,
developing, negotiating, structuring, acquiring, trading, settling, monitoring and holding portfolio
investments and prospective portfolio investments (whether or not consummated); travel, legal, tax and

accounting expenses in connection therewith; broken deal expenses; costs and expenses related to a
potential investment idea, including expenses related thereto which may consist of reimbursement to the
Advisor for a portion of the compensation paid to an employee or consultant of the Advisor including an
entrepreneur-in-residence and an applicable portion of the overhead of the Advisor; expenses related to the
registration, qualification or exemption of any Fund under any applicable laws; brokerage fees and
commissions and prime brokerage fees, clearing and settlement charges, bank services fees, custodial
expenses, agent bank and other bank service fees and other investment costs; payments to legal counsel,
tax advisors, auditors, accountants, administrators, directors, appraisers, custodians, consultants and other
outside advisors; expenses of the advisory boards attributable to any of the Funds; insurance; market data
...
Account Minimums and Types of Clients — Form ADV Part 2A (7/13/2026) [Brochure]
ITEM 7: TYPES OF CLIENTS

The Advisor’s clients are the Funds, the Separate Account, and co-investment vehicles. Each Fund’s
Governing Documents specify the eligibility criteria and minimum investment requirements. Although the
Advisor has the authority to accept subscriptions of a lesser amount, the required minimum initial
investment in the Funds can range from $500,000 to $5,000,000 depending on the Fund.

Investors in the Client Accounts and co-investment vehicles consist primarily of institutional investors,
financial institutions, other investment funds, pension plans, endowments, foundations, family offices, and
high-net-worth individuals. The Advisor requires Fund investors and co-investors to make representations
concerning their financial sophistication, eligibility to invest, and ability to bear the risk of loss of their
entire investment. The Advisor may, in its discretion, accept investors on terms that differ from those
offered to other investors, including through side letters or other arrangements, as permitted by the relevant
Governing Documents.
Sector Form 13F Holdings Value ($B)
Praxis Precision Medicines Inc 0.7
Celcuity Inc 0.4
Ascendis Pharma A/S 0.4
Roivant Sciences Ltd 0.2
Rhythm Pharmaceuticals Inc 0.2
Aeglea Biotherapeutics Inc 0.2
Nuvalent Inc 0.2
Edgewise Therapeutics Inc 0.1
Protagonist Therapeutics Inc 0.1
Apogee Therapeutics Inc 0.1
View All
Holdings by Sector ($B)
151296302011201620212027
Type Form D Funds Date Sold AUM
HF Perceptive Credit Opportunities Fund V LP [2026-02-23] 677.8 M
Filed 2025-10-29 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE Perceptive SP G LP 2025-03-26 7.2 M
Other PCOF Phoenix II AIV III LP 2024-03-28 1.2 M
PE Perceptive Capital Solutions Fund A LP [2024-03-28] 5.6 M 62.1 M
Filed 2025-02-04 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Not Applicable
PE Perceptive Capital Solutions Fund LP [2024-03-28] 218.8 M 364.4 M
Filed 2025-02-04 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Not Applicable
PE PX Venture C LLC [2024-03-20] 5.1 M
Filed 2023-07-18 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose
Other PCOF EQ AIV IV LP 2022-03-31 3.3 M
HF Perceptive Credit Opportunities Fund IV LP [2022-03-31] 1,495.1 M
Filed 2022-07-21 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Not Applicable
PE Perceptive SP C LP 2022-03-31 3.9 M
PE Perceptive SP D LP 2022-03-31 2.7 M
View All
AUM Breakdown Accounts AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 25 11.7
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 1 0.1
Total 26 11.8
By Discretionary
Discretionary 26 11.8
Non-Discretionary 0 0.0
Total 26 11.8
By Non-United States Persons
Non-United States Persons 4.6
United States Persons 7.1
Total 26 11.8
Form D Directors Role # Filings # Firms 2011 - 2026
Scott Dakers Director 141 35
Ernest Morrison Director 27 11
Joseph Edelman Director, Executive Officer 35 2
Perceptive Credit Opportunities GP LLC Director, Executive Officer 19 2
Perceptive Xontogeny Venture GP LLC Executive Officer 4 2
Perceptive Discovery GP LLC Executive Officer 3 2
Lev LB Holdings GP LLC Executive Officer 1 1
Perceptive LS GP LLC Executive Officer 1 1
EDGAR Form CIK 2011 - 2026
13F-HR [0001224962]
3 [0001224962]
4 [0001224962]
SC 13D [0001224962]
SC 13G [0001224962]
Form 13D/13G Filer Form 13D/13G Subject Filed
Perceptive Advisors LLC Research Alliance Corp IV [2026-07-20]
Perceptive Advisors LLC Kardigan Inc [2026-06-25]
Perceptive Advisors LLC Research Alliance Corp III [2026-05-28]
Perceptive Advisors LLC Avalyn Pharma Inc [2026-05-07]
Perceptive Advisors LLC Spyre Therapeutics Inc [2026-04-22]
Perceptive Advisors LLC Sutro Biopharma Inc [2026-04-21]
Perceptive Advisors LLC Zymeworks Inc [2026-04-15]
Perceptive Advisors LLC Relay Therapeutics Inc [2026-04-13]
Perceptive Advisors LLC Relay Therapeutics Inc [2026-03-19]
Perceptive Advisors LLC Edesa Biotech Inc [2026-03-16]
View All
Firm Profile (Form ADV)
Discretionary AUM$1.9B
ServesInstitutional
Fund TypesHedge Fund, Private Equity
LEI54930051M1DQYADROP30
Form 3/4/5 Subject 2011 - 2026
Immatics NV
Perceptive Advisors LLC
Perceptive Life Sciences Master Fund Ltd
Kardigan Inc
Edelman Joseph
MeiraGTx Holdings PLC
Solid Biosciences Inc
LeonaBio Inc
Perceptive Xontogeny Venture Fund II LP
Perceptive LS A LLC
View All
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Solid Biosciences Inc SLDB
Pre-Funded Warrant (right to buy) · derivative
2026-03-09 Grant 8,912,655 $5.61 49,999,995
MeiraGTx Holdings PLC MGTX
Ordinary Shares
2025-12-31 Disposed to issuer 2,300,000 $7.91 18,193,000
LeonaBio Inc ATHA
Series A Warrant (right to buy) · derivative
2025-12-23 Grant 1,279,526 $6.35 8,124,990
LeonaBio Inc ATHA
Pre-Funded Warrant (right to buy) · derivative
2025-12-23 Grant 1,372,935 $6.35 8,718,137
LeonaBio Inc ATHA
Series B Warrant (right to buy) · derivative
2025-12-23 Grant 3,543,307 $6.35 22,499,999
LeonaBio Inc ATHA
Common Stock
2025-12-23 Grant 329,756 $6.35 2,093,951
LeonaBio Inc ATHA
Pre-Funded Warrant (right to buy) · derivative
2025-12-23 Grant 457,645 $6.35 2,906,046
LeonaBio Inc ATHA
Series B Warrant (right to buy) · derivative
2025-12-23 Grant 1,181,101 $6.35 7,499,991
LeonaBio Inc ATHA
Common Stock
2025-12-23 Grant 989,270 $6.35 6,281,864
LeonaBio Inc ATHA
Pre-Funded Warrant (right to buy) · derivative
2025-12-23 Grant 5,502,402
LeonaBio Inc ATHA
Series A Warrant (right to buy) · derivative
2025-12-23 Grant 3,838,583 $6.35 24,375,002
Lyra Therapeutics Inc LYRA
Common Stock
2025-11-13 Sell 3,213 $3.90 12,531
Lyra Therapeutics Inc LYRA
Common Stock
2025-11-13 Sell 28,597 $3.90 111,528
Lyra Therapeutics Inc LYRA
Common Stock
2025-11-12 Sell 7,862 $4.06 31,920
Lyra Therapeutics Inc LYRA
Common Stock
2025-11-12 Sell 883 $4.06 3,585
Lyra Therapeutics Inc LYRA
Common Stock
2025-11-11 Sell 537 $4.31 2,314
Lyra Therapeutics Inc LYRA
Common Stock
2025-11-11 Sell 4,783 $4.31 20,615
Lyra Therapeutics Inc LYRA
Common Stock
2025-11-10 Sell 16,633 $4.54 75,514
Lyra Therapeutics Inc LYRA
Common Stock
2025-11-10 Sell 1,869 $4.54 8,485
Lyra Therapeutics Inc LYRA
Common Stock
2025-11-07 Sell 17,746 $4.75 84,294
showing 20 of 200 most recent transactions
Comparable Firms State AUM
BSP CLO Management LLC
NY 12.24 B
Pacific Private Fund Advisors LLC
CA 12.24 B
Canyon Capital Advisors LLC
TX 11.92 B
Levine Leichtman Capital Partners LLC
CA 11.88 B
Paradigm Operations LP
CA 11.87 B
Entrust Global Partners LLC
NY 11.82 B
TPG Solutions Advisors LLC
TX 11.61 B
One William Street Capital Management LP
NY 11.30 B
Guggenheim Corporate Funding LLC
NY 11.29 B
Orchard Global Asset Management LLP
11.28 B
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com